Evicenter
MarkdownMedical informationP&T meetings
VK2735

Chronic weight management

Last updated
184 sources

Clinical evidence

VENTURE

73 evidence topics · 13 sources

Objective
Location and study date
Registered study dates
FieldQuoted record
Study start (actual)“2023-08-31”
Primary completion (actual)“2024-02-27”
Study completion (actual)“2024-04-02”
Study design
Registered design and masking
FieldQuoted record
Allocation“Randomized”
Intervention model“Parallel Assignment”
Masking“Triple”
Eligibility criteria
Treatment
Study outcomes
Rationale for using percent change in body weight as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographic and clinical characteristics by dose arm, randomized population
CharacteristicPlacebo (n = 35)2.5 mg (n = 35)5.0 mg (n = 35)10 mg (n = 36)15 mg (n = 35)
Age, years, mean (SD)“47.6 (16.36)”View highlighted excerpt for this quote“49.7 (13.90)”View highlighted excerpt for this quote“51.8 (14.10)”View highlighted excerpt for this quote“47.1 (13.40)”View highlighted excerpt for this quote“51.3 (15.41)”View highlighted excerpt for this quote
Age 65 years or older, n (%)“4 (11.4)”View highlighted excerpt for this quote“8 (22.9)”View highlighted excerpt for this quote“8 (22.9)”View highlighted excerpt for this quote“4 (11.1)”View highlighted excerpt for this quote“8 (22.9)”View highlighted excerpt for this quote
Female, n (%)“29 (82.9)”View highlighted excerpt for this quote“27 (77.1)”View highlighted excerpt for this quote“23 (65.7)”View highlighted excerpt for this quote“24 (66.7)”View highlighted excerpt for this quote“27 (77.1)”View highlighted excerpt for this quote
White, n (%)“26 (74.3)”View highlighted excerpt for this quote“28 (80.0)”View highlighted excerpt for this quote“31 (88.6)”View highlighted excerpt for this quote“26 (72.2)”View highlighted excerpt for this quote“28 (80.0)”View highlighted excerpt for this quote
Black or African American, n (%)“8 (22.9)”View highlighted excerpt for this quote“7 (20.0)”View highlighted excerpt for this quote“2 (5.7)”View highlighted excerpt for this quote“10 (27.8)”View highlighted excerpt for this quote“6 (17.1)”View highlighted excerpt for this quote
Hispanic or Latino, n (%)“7 (20.0)”View highlighted excerpt for this quote“5 (14.3)”View highlighted excerpt for this quote“7 (20.0)”View highlighted excerpt for this quote“6 (16.7)”View highlighted excerpt for this quote“5 (14.3)”View highlighted excerpt for this quote
Weight, kg, mean (SD)“104.48 (22.18)”View highlighted excerpt for this quote“103.09 (19.01)”View highlighted excerpt for this quote“98.32 (13.18)”View highlighted excerpt for this quote“102.98 (18.27)”View highlighted excerpt for this quote“101.05 (18.91)”View highlighted excerpt for this quote
BMI, kg/m2, mean (SD)“38.88 (6.33)”View highlighted excerpt for this quote“38.03 (5.56)”View highlighted excerpt for this quote“35.86 (4.03)”View highlighted excerpt for this quote“36.62 (4.18)”View highlighted excerpt for this quote“36.63 (5.25)”View highlighted excerpt for this quote
Prediabetes, n (%)“14 (40.0)”View highlighted excerpt for this quote“21 (60.0)”View highlighted excerpt for this quote“21 (60.0)”View highlighted excerpt for this quote“16 (44.4)”View highlighted excerpt for this quote“16 (45.7)”View highlighted excerpt for this quote
Metabolic syndrome at baseline by dose arm
ArmMetS at baseline, n/N (%)
Placebo“18/34 (53)”
VK2735 2.5 mg“21/35 (60)”
VK2735 5.0 mg“22/35 (63)”
VK2735 10 mg“14/35 (40)”
VK2735 15 mg“13/35 (37)”
All VK2735“70/140 (50)”
Baseline cardiovascular risk factors in the cardiovascular risk analysis subset
CharacteristicPlacebo (n=27)All VK2735 (n=116)
Age, years, mean (SD)“51.9 (12.2)”“51.8 (12.1)”
Class 3 obesity, BMI 40 or higher, n (%)“13 (48.2)”“27 (23.3)”
Current smoker, n (%)“2 (7.4)”“15 (12.9)”
Current statin user, n (%)“5 (18.5)”“30 (25.9)”
Current hypertension medication user, n (%)“12 (44.4)”“40 (34.5)”
Efficacy results
Primary endpoint: percent change in body weight at week 13 by dose, mITT population
Categorical weight reduction of at least 5%, 10%, and 15% at week 13 by dose
Threshold and statisticPlacebo (n = 34)2.5 mg (n = 35)5.0 mg (n = 35)10 mg (n = 35)15 mg (n = 35)
At least 5% reduction, n (%)“4 (11.5)”View highlighted excerpt for this quote“28 (80.8)”View highlighted excerpt for this quote“34 (97.0)”View highlighted excerpt for this quote“33 (93.8)”View highlighted excerpt for this quote“35 (100)”View highlighted excerpt for this quote
At least 5%, odds ratio vs placebo (95% CI)Not applicable“26.7 (6.9, 103.2)”View highlighted excerpt for this quote“148.9 (20.8, > 999.9)”View highlighted excerpt for this quote“84.6 (15.6, 457.2)”View highlighted excerpt for this quote“454.1 (23.3, > 999.9)”View highlighted excerpt for this quote
At least 10% reduction, n (%)“1 (3.0)”View highlighted excerpt for this quote“14 (40.1)”View highlighted excerpt for this quote“23 (65.1)”View highlighted excerpt for this quote“25 (70.4)”View highlighted excerpt for this quote“31 (89.1)”View highlighted excerpt for this quote
At least 10%, odds ratio vs placebo (95% CI)Not applicable“23.6 (2.8, 197.5)”View highlighted excerpt for this quote“60.2 (7.1, 509.3)”View highlighted excerpt for this quote“91.5 (10.4, 806.8)”View highlighted excerpt for this quote“315.5 (30.6, > 999.9)”View highlighted excerpt for this quote
At least 10%, p value vs placeboNot applicable“0.0036”View highlighted excerpt for this quote“0.0002”View highlighted excerpt for this quote“< 0.0001”View highlighted excerpt for this quote“< 0.0001”View highlighted excerpt for this quote
At least 15% reduction, n (%)“0”View highlighted excerpt for this quote“4 (12.8)”View highlighted excerpt for this quote“4 (11.6)”View highlighted excerpt for this quote“11 (31.2)”View highlighted excerpt for this quote“15 (41.5)”View highlighted excerpt for this quote
At least 15%, odds ratio vs placebo (95% CI)Not applicable“11.2 (0.5, 228.2)”View highlighted excerpt for this quote“9.1 (0.4, 188.6)”View highlighted excerpt for this quote“35.9 (1.9, 677.1)”View highlighted excerpt for this quote“52.3 (2.8, 982.7)”View highlighted excerpt for this quote
At least 15%, p value vs placeboNot applicable“0.1163”View highlighted excerpt for this quote“0.1533”View highlighted excerpt for this quote“0.0169”View highlighted excerpt for this quote“0.0082”View highlighted excerpt for this quote
Topline release: placebo-adjusted weight change and 10% responders by dose
MeasurePlacebo (n=34)2.5 mg (n=35)5 mg (n=35)10 mg (n=35)15 mg (n=35)
Placebo-adjusted mean percent change from baselineNot applicable“-7.4 %”“-9.2 %”“-11.3 %”“-13.1 %”
Percent reporting at least 10% weight loss“4 %”“39 %”“62 %”“70 %”“88 %”
Off-treatment follow-up: weight loss persisting 4 and 7 weeks after the last dose
Time after final dose2.5 mg (n=17)5 mg (n=17)10 mg (n=18)15 mg (n=11)Combined VK2735 arms
Proportion of weight loss maintained, four weeks post final dose“98 %”“92 %”“92 %”“96 %”“94 %”
Proportion of weight loss maintained, seven weeks post final dose“91 %”“82 %”“75 %”“87 %”“83 %”
Pharmacokinetics in the follow-up subset
Representative PK parameter, VK2735 5.0 mgValue
Cmax, ng/mL“1,120”
AUC0-168, ng*h/mL“158,000”
Half-life, h“171”
Glycemic status: shift from prediabetes to normoglycemia and change in glucose and HbA1c
MeasurePlacebo (n = 35)2.5 mg (n = 35)5.0 mg (n = 35)10 mg (n = 36)15 mg (n = 35)
Prediabetes at baseline, n“14”View highlighted excerpt for this quote“21”View highlighted excerpt for this quote“21”View highlighted excerpt for this quote“16”View highlighted excerpt for this quote“16”View highlighted excerpt for this quote
Shift to normoglycemic, n (%)“4 (28.6)”View highlighted excerpt for this quote“17 (81.0)”View highlighted excerpt for this quote“16 (76.2)”View highlighted excerpt for this quote“10 (62.5)”View highlighted excerpt for this quote“15 (93.8)”View highlighted excerpt for this quote
Shift to diabetes, n (%)“1 (7.1)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Fasting glucose, mg/dL, baseline mean (SD)“99.37 (9.932)”View highlighted excerpt for this quote“100.31 (9.320)”View highlighted excerpt for this quote“99.77 (9.478)”View highlighted excerpt for this quote“97.97 (8.687)”View highlighted excerpt for this quote“99.06 (7.685)”View highlighted excerpt for this quote
Fasting glucose, mg/dL, change from baseline, LS mean (SE)“−0.37 (1.475)”View highlighted excerpt for this quote“−10.66 (1.439)”View highlighted excerpt for this quote“−10.23 (1.424)”View highlighted excerpt for this quote“−9.46 (1.424)”View highlighted excerpt for this quote“−10.85 (1.456)”View highlighted excerpt for this quote
HbA1c, %, baseline mean (SD)“5.49 (0.361)”View highlighted excerpt for this quote“5.51 (0.360)”View highlighted excerpt for this quote“5.43 (0.399)”View highlighted excerpt for this quote“5.50 (0.357)”View highlighted excerpt for this quote“5.50 (0.312)”View highlighted excerpt for this quote
HbA1c, %, change from baseline, LS mean (SE)“0.03 (0.041)”View highlighted excerpt for this quote“−0.29 (0.040)”View highlighted excerpt for this quote“−0.27 (0.040)”View highlighted excerpt for this quote“−0.27 (0.039)”View highlighted excerpt for this quote“−0.36 (0.040)”View highlighted excerpt for this quote
Blood pressure change at week 13 by dose
MeasurePlacebo (n = 35)2.5 mg (n = 35)5.0 mg (n = 35)10 mg (n = 36)15 mg (n = 35)
Systolic blood pressure, mmHg, baseline mean (SD)“125.10 (13.963)”View highlighted excerpt for this quote“126.20 (14.754)”View highlighted excerpt for this quote“128.60 (15.253)”View highlighted excerpt for this quote“122.64 (13.764)”View highlighted excerpt for this quote“123.36 (14.531)”View highlighted excerpt for this quote
Systolic blood pressure, mmHg, change from baseline, LS mean (SE)“−4.20 (1.993)”View highlighted excerpt for this quote“−6.87 (1.906)”View highlighted excerpt for this quote“−6.71 (1.931)”View highlighted excerpt for this quote“−7.04 (1.936)”View highlighted excerpt for this quote“−10.97 (2.000)”View highlighted excerpt for this quote
Diastolic blood pressure, mmHg, baseline mean (SD)“80.93 (9.169)”View highlighted excerpt for this quote“81.56 (9.491)”View highlighted excerpt for this quote“82.91 (7.904)”View highlighted excerpt for this quote“79.00 (9.420)”View highlighted excerpt for this quote“78.39 (7.332)”View highlighted excerpt for this quote
Diastolic blood pressure, mmHg, change from baseline, LS mean (SE)“−1.68 (1.286)”View highlighted excerpt for this quote“−3.27 (1.229)”View highlighted excerpt for this quote“−4.34 (1.246)”View highlighted excerpt for this quote“−2.37 (1.247)”View highlighted excerpt for this quote“−5.16 (1.290)”View highlighted excerpt for this quote
Lipids and other cardiometabolic parameters, combined VK2735 arms versus placebo
ParameterMean difference, VK2735 compared with placeboStandardized mean difference (95% CI)
Total cholesterol, mg/dL“–8.03”“–0.26 (–0.75, 0.22)”
Triglycerides, mg/dL“–11.90”“–0.22 (–0.70, 0.27)”
LDL, mg/dL“–3.98”“–0.14 (–0.63, 0.34)”
HbA1c, %“–0.32”“–1.49 (–2.01, –0.97)”
BMI, kg/m²“–3.52”“–2.32 (–2.90, –1.75)”
SBP, mmHg“–2.40”“–0.20 (–0.69, 0.28)”
Predicted 10-year cardiovascular risk at week 13, post hoc analysis
Predicted 10-year riskLS mean difference in percent change from baseline, VK2735 vs placebo (95% CI)P value
Cardiovascular disease“–4.14 (–17.22, 8.94)”“.532”
Atherosclerotic cardiovascular disease“–6.67 (–19.44, 6.09)”“.303”
Heart failure“–16.21 (–27.37, –5.06)”“.005”
BMI category shifts from baseline to week 13, exploratory analysis
Baseline category and transitionVK2735 combinedPlacebo
Class III obesity at baseline, n“n=35”“n=15”
Class III, transitioning to Class II“57 %”“13 %”
Class III, transitioning to Class I“11 %”“0 %”
Class III, no change in obesity class“31 %”“87 %”
Class II obesity at baseline, n“n=51”“n=10”
Class II, transitioning to Class I“80 %”“20 %”
Class II, transitioning to overweight“2 %”“0 %”
Class II, no change in obesity class“18 %”“80 %”
Class I obesity at baseline, n“n=46”“n=8”
Class I, transitioning to overweight“65 %”“12 %”
Class I, transitioning to normal weight“9 %”“0 %”
Class I, no change in obesity class“26 %”“75%”
Overweight at baseline, n“n=8”“n=1”
Overweight, transitioning to normal weight“50 %”“0 %”
Cardiometabolic markers by BMI category change among VK2735-treated participants
Marker, mean (SD)Baseline (N=124)Change with at least one BMI category improvement (N=89)Change with no BMI category change (N=35)
Hemoglobin A1C, %“5.49 (0.36)”“-0.34 (0.25)”“-0.25 (0.17)”
Glucose, mg/dL“99.8 (8.77)”“-12.4 (9.69)”“-10.1 (8.56)”
Triglycerides, mg/dL“122.1 (62.16)”“-20.1 (56.76)”“-2.2 (52.40)”
Waist circumference, cm“112.7 (11.34)”“-10.1 (5.90)”“-7.7 (4.24)”
Systolic blood pressure, mmHg“124.5 (14.53)”“-9.0 (12.26)”“-6.0 (13.47)”
Diastolic blood pressure, mmHg“80.1 (8.69)”“-4.2 (8.27)”“-2.8 (8.97)”
LDL cholesterol, mg/dL“116.7 (33.12)”“-12.3 (27.61)”“-6.9 (23.45)”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Overall treatment-emergent adverse events and severity
Discontinuation due to adverse events by dose
Gastrointestinal adverse events by dose, all causality
Preferred term, n (%)Placebo (n = 35)2.5 mg (n = 35)5.0 mg (n = 35)10 mg (n = 35)15 mg (n = 35)
Gastrointestinal disorders, any“13 (37)”View highlighted excerpt for this quote“18 (51)”View highlighted excerpt for this quote“23 (66)”View highlighted excerpt for this quote“25 (71)”View highlighted excerpt for this quote“29 (83)”View highlighted excerpt for this quote
Nausea“7 (20)”View highlighted excerpt for this quote“9 (26)”View highlighted excerpt for this quote“16 (46)”View highlighted excerpt for this quote“13 (37)”View highlighted excerpt for this quote“22 (63)”View highlighted excerpt for this quote
Constipation“4 (11)”View highlighted excerpt for this quote“7 (20)”View highlighted excerpt for this quote“10 (29)”View highlighted excerpt for this quote“9 (26)”View highlighted excerpt for this quote“10 (29)”View highlighted excerpt for this quote
Diarrhea“3 (9)”View highlighted excerpt for this quote“11 (31)”View highlighted excerpt for this quote“6 (17)”View highlighted excerpt for this quote“7 (20)”View highlighted excerpt for this quote“4 (11)”View highlighted excerpt for this quote
Vomiting“0”View highlighted excerpt for this quote“3 (9)”View highlighted excerpt for this quote“6 (17)”View highlighted excerpt for this quote“6 (17)”View highlighted excerpt for this quote“10 (29)”View highlighted excerpt for this quote
Gastroesophageal reflux disease“1 (3)”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“5 (14)”View highlighted excerpt for this quote“4 (11)”View highlighted excerpt for this quote“6 (17)”View highlighted excerpt for this quote
Abdominal pain“1 (3)”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote
Eructation“0”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“3 (9)”View highlighted excerpt for this quote
Decreased appetite“0”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“5 (14)”View highlighted excerpt for this quote“9 (26)”View highlighted excerpt for this quote“6 (17)”View highlighted excerpt for this quote
Drug-related gastrointestinal adverse events by severity and dose
Event and severity, n (%)Placebo (n = 35)2.5 mg (n = 35)5.0 mg (n = 35)10 mg (n = 35)15 mg (n = 35)
Any gastrointestinal disorder, mild“8 (23)”View highlighted excerpt for this quote“8 (23)”View highlighted excerpt for this quote“14 (40)”View highlighted excerpt for this quote“13 (37)”View highlighted excerpt for this quote“16 (46)”View highlighted excerpt for this quote
Any gastrointestinal disorder, moderate“4 (11)”View highlighted excerpt for this quote“7 (20)”View highlighted excerpt for this quote“9 (26)”View highlighted excerpt for this quote“7 (20)”View highlighted excerpt for this quote“10 (29)”View highlighted excerpt for this quote
Any gastrointestinal disorder, severe“0”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“3 (9)”View highlighted excerpt for this quote
Nausea, mild“7 (20)”View highlighted excerpt for this quote“5 (14)”View highlighted excerpt for this quote“11 (31)”View highlighted excerpt for this quote“8 (23)”View highlighted excerpt for this quote“15 (43)”View highlighted excerpt for this quote
Nausea, moderate“0”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“5 (14)”View highlighted excerpt for this quote“4 (11)”View highlighted excerpt for this quote“7 (20)”View highlighted excerpt for this quote
Constipation, mild“2 (6)”View highlighted excerpt for this quote“3 (9)”View highlighted excerpt for this quote“8 (23)”View highlighted excerpt for this quote“6 (17)”View highlighted excerpt for this quote“9 (26)”View highlighted excerpt for this quote
Constipation, moderate“2 (6)”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote
Vomiting, mild“0”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“4 (11)”View highlighted excerpt for this quote“5 (14)”View highlighted excerpt for this quote“5 (14)”View highlighted excerpt for this quote
Vomiting, moderate“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“3 (9)”View highlighted excerpt for this quote
Diarrhea, mild“2 (6)”View highlighted excerpt for this quote“4 (11)”View highlighted excerpt for this quote“5 (14)”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote
Diarrhea, moderate“0”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“3 (9)”View highlighted excerpt for this quote
Adverse events of special interest: pancreatitis, gallbladder events, and injection site reactions
Heart rate and blood pressure as reported on the 2024 congress poster
Vital signPlacebo2.5 mg5 mg10 mg15 mg
Heart rate, bpm, baseline“65.7”“63.5”“66.9”“64.3”“63.9”
Heart rate, bpm, mean change at week 13“4.4”“3.8”“5.0”“10.8”“7.1”
Systolic blood pressure, mmHg, mean change at week 13“-4.4”“-7.4”“-8.8”“-5.4”“-9.6”
Diastolic blood pressure, mmHg, mean change at week 13“-2.2”“-3.7”“-5.5”“-1.5”“-4.3”
Other selected adverse events by dose: hypotension, dizziness, fatigue, lipase, and hyperthyroidism
Preferred term, n (%)Placebo (n = 35)2.5 mg (n = 35)5.0 mg (n = 35)10 mg (n = 35)15 mg (n = 35)
Hypotension“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote
Dizziness“1 (3)”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“4 (11)”View highlighted excerpt for this quote
Fatigue“1 (3)”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“5 (14)”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“4 (11)”View highlighted excerpt for this quote
Headache“4 (11)”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“4 (11)”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“4 (11)”View highlighted excerpt for this quote
Lipase increased“0”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Hyperthyroidism“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Study limitations
Summary: limitations of the VENTURE evidence

VENTURE was a phase 2 dose-finding trial of 13 weeks of treatment in 176 randomized participants, about 35 per arm, conducted at 20 United States sites. The authors state that it was “limited in size and duration” and “not powered to determine statistical significance for differences between treatment groups for most parameters.” The sample size calculation of 29 participants per arm was based on a two-sample t-test. A 13-week result does not address the FDA draft guidance benchmark, which assesses effectiveness after 1 year of treatment at the maintenance dosage. The topline release reported no weight-loss plateau at week 13, and the authors state that “Maximal therapeutic levels were likely not yet achieved in this limited duration study.”

People with diabetes were excluded, BMI above 50 kg/m2 was excluded, and the randomized population was mostly female and White, with between 65.7% and 82.9% female and between 72.2% and 88.6% White participants per arm. The 15 mg arm started at 5.0 mg while the other arms started at 2.5 mg, and the authors state that the “titration schedule and dosing, will be changed to optimize tolerability in future studies.”

The primary analysis was a mixed model for repeated measures in the modified intent-to-treat population (174 participants), with assessments more than 9 days after treatment discontinuation set to missing and data assumed missing at random. This corresponds to an on-treatment estimand; no treatment-policy analysis that retains off-treatment weights was reported. Off-treatment weight data at weeks 16 and 19 were reported only for a pharmacokinetic subset of 75 participants (63 VK2735, 12 placebo). Responder analyses, which the FDA draft guidance states may “inappropriately exaggerate treatment effects”, were secondary endpoints.

Reported figures differ between documents. The topline release reported 23 participants (13%) discontinuing treatment and 10% responder proportions of 4%, 39%, 62%, 70%, and 88%, while the publication reported 24 of 176 (14%) and 3.0%, 40.1%, 65.1%, 70.4%, and 89.1%. Baseline heart rate on the 2024 poster (63.5 to 66.9 bpm) differs from the publication (69.3 to 74.2 bpm), as does the week 13 heart rate change (3.8 to 10.8 bpm versus 3.3 to 9.3 bpm in active arms). Mean heart rate increased by up to 9.3 bpm in the 10 mg arm versus 1.4 bpm with placebo in the publication. Treatment discontinuation due to adverse events rose with dose, from 1 of 35 (3%) at 2.5 mg to 7 of 35 (20%) at 15 mg, with none on placebo.

The metabolic syndrome, BMI category, and predicted cardiovascular risk analyses were exploratory or post hoc, reported in company releases and congress posters without peer review, used observed values without imputation, and reported no adjustment for multiplicity. The cardiovascular risk subset comprised 143 participants, of whom 110 (20 placebo, 90 VK2735) entered the risk model, and all authors of that poster are company employees. No health-related quality of life or patient-reported outcome was reported. The trial was funded by Viking Therapeutics, and every author of the publication was a site investigator or a company employee. No results are posted on ClinicalTrials.gov.